<DOC>
	<DOC>NCT02403349</DOC>
	<brief_summary>Confirm central blood pressure reduction effect of Fimasartan, Valsartan and Atenolol and compare correlation with the measured peripheral (central blood pressure, pulse wave velocity, and flow-mediated dilation) and cerebral blood flow factors (transcranial doppler findings, cerebral blood flow volume) in acute ischemic stroke patients with hypertension.</brief_summary>
	<brief_title>Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Age ≥ 30 years old Acute ischemic stroke patient who has corresponding DWI(diffusion weighted imaging) lesion correlated with symptom after 7days, but within 28days from stroke onset Diagnosed with Hypertension hypertensive patients who taking antihypertensive drugs or SBP≥140mmHg Informed consent Patients with hemorrhagic Stroke Patients with severe Stroke over NIHss(National Institutes of Health stroke scale) 16 Uncontrolled hypertension (SBP ≥200mmHg) Patients with history of allergic reaction to any angiotensin II antagonist Liver disease(more than double to normal level, SGOT(serum glutamicoxaloacetic transaminase ), SGPT(serum glutamicpyruvic transaminase ), total bilirubin) Renal disease(serum creatinine ≥2.0mg/dl) Anemia(Hb &lt; 8mg/dl) Thrombocytopenia( &lt; 10^3/ml) Patients with secondary hypertension Childbearing and breastfeeding women Otherwise inappropriate patients depending on the investigator's decision</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>